First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2026 revenue reaching $47.3B — -1.9% growth in a single year.
What’s Driving the Stock
1Bristol-Myers Squibb's recent clinical trial for a new immunotherapy showed a 35% improvement in patient outcomes compared to existing treatments, positioning it favorably against competitors.
2The company's strategic partnership with a leading biotech firm for co-development of a novel cancer therapy could unlock $5B in potential revenue over the next five years.
3Recent patent extensions for key drugs like Opdivo could delay generic competition by an additional 3 years, securing revenue streams.
4A significant increase in R&D spending to $8B in FY26, aimed at accelerating pipeline development, could lead to new product launches.
5Advancements in personalized medicine and targeted therapies
6Increased focus on immunotherapy in cancer treatment
7FDA approvals for new drugs or indications, particularly in oncology
8Clinical trial results for pipeline candidates, especially in immunology
"Management emphasized, 'Our innovative pipeline is stronger than ever, positioning us to lead in oncology and immunology.'"
Moat: Bristol-Myers Squibb's competitive advantage lies in its strong portfolio of patented drugs and a robust R&D pipeline.
growth - due to the company's strong pipeline and potential for revenue growth from new drug approvals.
Higher interest rates can increase the cost of capital for R&D investments, potentially impacting future growth.
Watch on earnings: FDA approval rates for new drugs, Market share in oncology and immunology, R&D pipeline progress and clinical trial outcomes.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $47.3B to $46.3B as bristol-myers squibb's recent clinical trial for a new immunotherapy showed a 35% improvement in patient outcomes.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.